Protalix signs deal with Pfizer to advance Gaucher disease drug trials
According to the clinical development agreement, Protalix will continue to manage and fund Elelyso (taliglucerase alfa) ongoing trials while the new studies of the enzyme replacement therapy will
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.